Factors affecting dialysis duration in children with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome

被引:0
|
作者
Khalid, Myda [1 ]
Miller, Chloe [1 ]
Gebregziabher, Netsanet [2 ]
Guckien, Zoe [1 ]
Goswami, Shrea [1 ]
Perkins, Anthony [2 ]
Andreoli, Sharon Phillips [1 ]
机构
[1] Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA
关键词
Shiga toxin-producing Escherichia coli; Hemolytic uremic syndrome; Children; Dialysis; STEC-HUS; NSAID; Hematocrit; White blood cell count; Platelet count; PLATELET TRANSFUSIONS; DIARRHEA; INVOLVEMENT; NEUTROPHILS; PREDICTORS; STRICTURE; HYDRATION; OUTCOMES; RISK;
D O I
10.1007/s00467-022-05839-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Predicting disease severity can be informative for management of HUS. Dialysis requirement, volume depletion, elevated white blood cell counts, very young age, and use of antimotility agents are known factors associated with severe HUS.Methods A retrospective cohort analysis was performed to identify factors associated with dialysis duration using electronic medical record and chart review of 76 children <= 18 years of age at presentation with STEC-HUS identified through billing data from July 2008 to April 2020 at James Whitcomb Riley Hospital for Children, Indiana University, Indiana.Results Novel findings associated with prolonged dialysis duration were age >= 6 years old at presentation (p = 0.041) and lack of drop in platelets below 60,000/mm(3) anytime during the illness (p = 0.015). In addition, children with NSAID exposure trended longer on dialysis: 15 days with vs. 10 days without (p = 0.117). Known risk factors for severe disease including elevated peak white blood cell (WBC) count and higher hematocrit at presentation were also associated with longer dialysis duration: children with peak WBC > 20,000/mm(3) were on dialysis for 15 vs. 9.5 days (p = 0.002) and in children on dialysis <= 14 days hematocrit at presentation was 29.6% vs. 24.2% (p = 0.03). Children requiring dialysis for 20 days or longer were more likely to be on anti-hypertensive medications (p = 0.025) and have chronic kidney disease at 12-month follow up (p = 0.044).Conclusions Age >= 6, elevated WBC count > 20,000/mm(3), higher hematocrit at presentation, lack of drop in platelets to < 60,000/mm(3), and possibly NSAID exposure during illness are associated with longer dialysis duration in STEC-HUS.
引用
收藏
页码:2753 / 2761
页数:9
相关论文
共 50 条
  • [11] Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndrome
    Laura Fernanda Alconcher
    Marta Rivas
    Lucas Ivan Lucarelli
    Jimena Galavotti
    Mabel Rizzo
    European Journal of Clinical Microbiology & Infectious Diseases, 2020, 39 : 427 - 432
  • [12] Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome
    Liu, Yang
    Thaker, Hatim
    Wang, Chunyan
    Xu, Zhonggao
    Dong, Min
    TOXINS, 2023, 15 (01)
  • [13] Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndrome
    Fernanda Alconcher, Laura
    Rivas, Marta
    Ivan Lucarelli, Lucas
    Galavotti, Jimena
    Rizzo, Mabel
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020, 39 (03) : 427 - 432
  • [14] Stratified therapy in Shiga toxin-producing Escherichia coli associated with hemolytic uremic syndrome
    Ashida, Akira
    PEDIATRICS INTERNATIONAL, 2020, 62 (03) : 305 - 306
  • [15] Hemolytic uremic syndrome and encephalopathy from Shiga toxin-producing Escherichia coli
    Ishihara, Toru
    Ozawa, Hideki
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (29) : E817 - E817
  • [16] Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing Escherichia coli 0111
    Azadi, Reza
    Calabrese, Kenneth
    Stroup, Jeffrey
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (09): : 538 - 544
  • [17] Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection
    Bruyand, M.
    Mariani-Kurkdjian, P.
    Gouali, M.
    de Valk, H.
    King, L. A.
    Le Hello, As.
    Bonacorsi, S.
    Loirat, C.
    MEDECINE ET MALADIES INFECTIEUSES, 2018, 48 (03): : 167 - 174
  • [18] Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome Retrospective Genetic and Clinical Study
    Fremeaux-Bacchi, Veronique
    Sellier-Leclerc, Anne-Laure
    Vieira-Martins, Paula
    Limou, Sophie
    Kwon, Theresa
    Lahoche, Annie
    Novo, Robert
    Llanas, Brigitte
    Nobili, Francois
    Roussey, Gwenaelle
    Cailliez, Mathilde
    Ulinski, Tim
    Deschenes, Georges
    Alberti, Corinne
    Weill, Francois-Xavier
    Mariani, Patricia
    Loirat, Chantal
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 14 (03): : 364 - 377
  • [19] Shiga Toxin-Producing Escherichia coli and the Hemolytic-Uremic Syndrome REPLY
    Freedman, Stephen B.
    Van de Kar, Nicole C. A. J.
    Tarr, Phillip I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (26): : 2500 - 2500
  • [20] Infections in Pediatric Postdiarrheal Hemolytic Uremic Syndrome Factors Associated With Identifying Shiga Toxin-Producing Escherichia coli
    Mody, Rajal K.
    Luna-Gierke, Ruth E.
    Jones, Timothy F.
    Comstock, Nicole
    Hurd, Sharon
    Scheftel, Joni
    Lathrop, Sarah
    Smith, Glenda
    Palmer, Amanda
    Strockbine, Nancy
    Talkington, Deborah
    Mahon, Barbara E.
    Hoekstra, Robert M.
    Griffin, Patricia M.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2012, 166 (10): : 902 - 909